TY - JOUR
T1 - New cancers after autotransplantations for multiple myeloma
AU - Mahindra, Anuj
AU - Raval, Girindra
AU - Mehta, Paulette
AU - Brazauskas, Ruta
AU - Zhang, Mei Jie
AU - Zhong, Xiaobo
AU - Bird, Jennifer M.
AU - Freytes, César O.
AU - Hale, Gregory A.
AU - Herzig, Roger
AU - Holmberg, Leona A.
AU - Kamble, Rammurti T.
AU - Kumar, Shaji
AU - Lazarus, Hillard M.
AU - Majhail, Navneet S.
AU - Marks, David I.
AU - Moreb, Jan S.
AU - Olsson, Richard
AU - Saber, Wael
AU - Savani, Bipin N.
AU - Schiller, Gary J.
AU - Tay, Jason
AU - Vogl, Dan T.
AU - Waller, Edmund K.
AU - Wiernik, Peter H.
AU - Wirk, Baldeep
AU - Lonial, Sagar
AU - Krishnan, Amrita Y.
AU - Dispenzieri, Angela
AU - Brandenburg, Nancy A.
AU - Gale, Robert Peter
AU - Hari, Parameswaran N.
N1 - Publisher Copyright:
© 2015 American Society for Blood and Marrow Transplantation.
PY - 2015/4/1
Y1 - 2015/4/1
N2 - We describe baseline incidence and risk factors for new cancers in 4161 persons receiving autotransplants for multiple myeloma in the United States from 1990 to 2010. Observed incidence of invasive new cancers was compared with expected incidence relative to the US population. The cohort represented 13,387 person-years at-risk. In total, 163 new cancers were observed, for a crude incidence rate of 1.2 new cancers per 100 person-years and cumulative incidences of 2.6% (95% confidence interval [CI], 2.09 to 3.17), 4.2% (95% CI, 3.49 to 5.00), and 6.1% (95% CI, 5.08 to 7.24) at 3, 5, and 7years, respectively. The incidence of new cancers in the autotransplantation cohort was similar to age-, race-, and gender-adjusted comparison subjects with an observed/expected (O/E) ratio of 1.00 (99% CI, .81 to 1.22). However, acute myeloid leukemia and melanoma were observed at higher than expected rates with O/E ratios of 5.19 (99% CI, 1.67 to 12.04; P=0004), and 3.58 (99% CI, 1.82 to 6.29; P < .0001), respectively. Obesity, older age, and male gender were associated with increased risks of new cancers in multivariate analyses. This large data set provides a baseline for comparison and defines the histologic type specific risk for new cancers in patients with MM receiving postautotransplantation therapies, such as maintenance.
AB - We describe baseline incidence and risk factors for new cancers in 4161 persons receiving autotransplants for multiple myeloma in the United States from 1990 to 2010. Observed incidence of invasive new cancers was compared with expected incidence relative to the US population. The cohort represented 13,387 person-years at-risk. In total, 163 new cancers were observed, for a crude incidence rate of 1.2 new cancers per 100 person-years and cumulative incidences of 2.6% (95% confidence interval [CI], 2.09 to 3.17), 4.2% (95% CI, 3.49 to 5.00), and 6.1% (95% CI, 5.08 to 7.24) at 3, 5, and 7years, respectively. The incidence of new cancers in the autotransplantation cohort was similar to age-, race-, and gender-adjusted comparison subjects with an observed/expected (O/E) ratio of 1.00 (99% CI, .81 to 1.22). However, acute myeloid leukemia and melanoma were observed at higher than expected rates with O/E ratios of 5.19 (99% CI, 1.67 to 12.04; P=0004), and 3.58 (99% CI, 1.82 to 6.29; P < .0001), respectively. Obesity, older age, and male gender were associated with increased risks of new cancers in multivariate analyses. This large data set provides a baseline for comparison and defines the histologic type specific risk for new cancers in patients with MM receiving postautotransplantation therapies, such as maintenance.
UR - https://www.scopus.com/pages/publications/84924259698
UR - https://www.scopus.com/pages/publications/84924259698#tab=citedBy
U2 - 10.1016/j.bbmt.2014.12.028
DO - 10.1016/j.bbmt.2014.12.028
M3 - Article
C2 - 25555448
AN - SCOPUS:84924259698
SN - 1083-8791
VL - 21
SP - 738
EP - 745
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 4
ER -